文献速递治疗药物监测与药物基因组学特殊人群用药

基于4700例患者代谢比评估CYP2D6单倍型活性评分

Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates.
PubMed 文献 · Clin Pharmacol Ther · 2021-05-02

本研究回顾性分析4700例经CYP2D6基因分型并使用利培酮、文拉法辛和/或阿立哌唑患者的治疗药物监测数据,以代谢比量化CYP2D6基因型对代谢活性的影响。结果显示CYP2D6*41和CYP2D6*9-10等位基因活性分别约为正常等位基因的六分之一和三分之一,为基因型向代谢表型转化提供了依据。

要点

  • CYP2D6*41和CYP2D6*9-10等位基因活性分别约为正常等位基因的1/6和1/3。
  • 基于利培酮、文拉法辛、阿立哌唑代谢比可量化CYP2D6二倍型相对活性。
  • 本研究为CYP2D6基因型向药物代谢表型转化提供依据。

核心结论

  • CYP2D6*41和CYP2D6*9-10等位基因活性分别约为正常等位基因的六分之一和三分之一。
  • 本研究结果为CYP2D6基因型向药物代谢表型转化提供了坚实基础。

研究设计与样本

  • 回顾性分析4700例CYP2D6基因分型患者的治疗药物监测数据,患者使用利培酮、文拉法辛和/或阿立哌唑。
  • 根据正常功能(CYP2D6Norm)、无功能(CYP2D6Nonf)和功能减低(CYP2D6Decr;即CYP2D6*9、CYP2D6*10和CYP2D6*41)单倍型将患者分为二倍型。

主要发现

  • 同时使用利培酮和文拉法辛、利培酮和阿立哌唑、文拉法辛和阿立哌唑的患者(n=77-103)代谢比显著相关(ρ=0.874、0.785和0.644,P均<0.001)。
  • 相对CYP2D6二倍型活性:CYP2D6Nonf/*41为7.0%,CYP2D6Nonf/*9-10为16.7%,CYP2D6*41/*41为13.2%,CYP2D6*41/*9-10为24.9%,CYP2D6*9-10/*9-10为33.1%,CYP2D6Nonf/Norm为41.3%,CYP2D6*41/Norm为55.0%,CYP2D6*9-10/Norm为58.9%,CYP2D6Norm/Normx2为149.2%。

关键数值与推荐

  • 相对代谢活性以CYP2D6Nonf/Nonf亚组中位数为0%、CYP2D6Norm/Norm亚组中位数为100%计算。
  • CYP2D6*41和CYP2D6*9-10等位基因活性评分分别估计为正常等位基因的六分之一和三分之一。

临床怎么用

  • 可将CYP2D6*41和CYP2D6*9-10等位基因活性评分用于CYP2D6基因型向代谢表型转化,辅助个体化用药剂量调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The metabolic activity of the polymorphic CYP2D6 enzyme is dependent on the CYP2D6 genotype; however, the guidelines for translating the genotype into phenotype, which are of relevance for adequate drug dose personalization, are ambiguous. In the present study, retrospective therapeutic drug monitoring data from 4,700 CYP2D6 genotyped patients treated with risperidone, venlafaxine, and/or aripiprazole were analyzed to quantify the effect of CYP2D6 genotype on the CYP2D6 metabolic activities, as measured by metabolic ratios of these substrates. The patients were categorized into diplotypes based on the presence of normal function (CYP2D6Norm), nonfunctional (CYP2D6Nonf), and decreased function (CYP2D6Decr; i.e., CYP2D6*9, CYP2D6*10, and CYP2D6*41) CYP2D6 haplotypes. Significant correlations between the metabolic ratios were observed in patients (n = 77-103) cotreated with risperidone and venlafaxine, risperidone and aripiprazole, or venlafaxine and aripiprazole (ρ = 0.874, 0.785, and 0.644, respectively; P < 0.001 for all). Relative metabolic CYP2D6 diplotype activity was calculated based on that the metabolic ratios, where median values for CYP2D6Nonf/Nonf and CYP2D6Norm/Norm subgroups were set to 0% and 100%, respectively. The relative CYP2D6 activities were: 7.0% for CYP2D6Nonf/*41, 16.7% for CYP2D6Nonf/*9-10, 13.2% for CYP2D6*41/*41, 24.9% for CYP2D6*41/*9-10, 33.1% for CYP2D6*9-10/*9-10, 41.3% for CYP2D6Nonf/Norm, 55.0% for CYP2D6*41/Norm, 58.9% for CYP2D6*9-10/Norm, and 149.2% for CYP2D6Norm/Normx2. Compared with the CYP2D6Norm alleles, the activity scores of CYP2D6*41 and CYP2D6*9-10 alleles were estimated to be one sixth and one third, respectively. The results of this highly powered study provide a solid basis for the translation of the CYP2D6 genotype into a drug metabolic phenotype.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jukić MM, Smith RL, Molden E, et al. Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates. Clin Pharmacol Ther. 2021. PMID: 33792048. doi:10.1002/cpt.2246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。